ArticleMalaria journal2025
Immunogenicity and gene polymorphism analysis of Plasmodium ovale wallikeri glycosylphosphatidylinositol-anchored micronemal antigen (GAMA).
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe glycosylphosphatidylinositol-anchored micronemal antigen (GAMA) protein is integral to the invasion of erythrocytes by Plasmodium species, with well-documented roles in the merozoite binding of both Plasmodium falciparum and Plasmodium vivax. In the malaria endemic areas infections caused by Plasmodium ovale spp. can escalate to severe malaria, characterized by life-threatening anaemia. Nevertheless, P. ovale spp. have been frequently neglected in the study, and the species-specific P. ovale wallikeri (Pow) GAMA (PowGAMA) protein remains uncharacterized. This study investigates the genetic diversity of P. ovale spp. imported from Africa and evaluates the immunogenicity of recombinant PowGAMA (rPowGAMA).
methodsThe study conducted an analysis of 56 P. ovale isolates, comprising 38 P. ovale wallikeri and 18 P. ovale curtisi, collected from Africa between 2012 and 2016. The powgama gene was subjected to polymerase chain reaction (PCR) amplification, sequencing, and genetic diversity analysis utilizing DnaSP v6 software. The rPowGAMA protein was expressed in Escherichia coli, subsequently purified, and employed to immunize BALB/c mice. The antigenicity of rPowGAMA was evaluated through immunoblotting, while immune responses were assessed utilizing enzyme-linked immunosorbent assay (ELISA) and splenocyte proliferation assays. Additionally, cytokine production was quantified through ELISA. Seroreactivity was determined via protein microarray analysis using sera from 30 individuals infected with P. ovale and 20 healthy controls.
resultsA genetic analysis of 38 P. ovale wallikeri isolates revealed 10 single nucleotide polymorphism (SNP) sites within the powgama gene, with nucleotide diversity (π) ranging from 0 to 0.00435. The isolates were categorized into 13 distinct haplotypes (Hd = 0.812), indicating moderate genetic diversity. Notably, conserved regions approximately 2.3 kb in length (π ≈ 0) were identified, particularly within functional domains. Immunization with the rPowGAMA protein, spanning amino acids 276 to 646, elicited a robust Th1-polarized immune response in mice. This response was characterized by notably high production of IFN-γ and significant lymphocyte proliferation, culminating in an endpoint antibody titer of 1:5,120,000 and an avidity of 78.37%. The protein demonstrated 83.3% sensitivity and 70% specificity in detecting natural infections.
conclusionThis study illustrates the significant conservation of powgama gene sequences among P. ovale isolates. The rPowGAMA expressed from this conserved sequence demonstrates substantial immunogenicity, eliciting both high-avidity antibodies and robust T-cell responses. These findings indicate the potential of rPowGAMA to elicit dual protective immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.